Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript

SA Transcripts158.92K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call March 11, 2026 8:30 AM EDT Company Participants Jayson Rieger - President, CEO & DirectorJohn Kirby - Interim Chief Financial OfficerChris Chapman - Chief Commercial OfficerDavid Zawitz - Chief Operating Officer Conference Call Participants Kevin Gardner - Lifesci Advisors, LLCStacy Ku - TD Cowen, Research DivisionGeorgia Bank - Jefferies LLC, Research DivisionJohn Todaro - Needham & Company, LLC, Research DivisionBrian Kemp Dolliver - Brookline Capital Markets, LLC, Research DivisionDev Prasad - Lucid Capital Markets, LLC, Research DivisionRaghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to the Verrica Pharmaceuticals Fourth Quarter and Year-End 2025 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSci Advisors. You may begin your conference. Kevin GardnerLifesci Advisors, LLC Thank you, operator. Hello, everyone, and welcome to Verrica Pharmaceuticals Fourth Quarter and Year-End 2025 Corporate Update Conference Call. With me on the line this morning are Jayson Rieger, President and Chief Executive Officer; Noah Rosenberg, Chief Medical Officer; John Kirby, Interim Chief Financial Officer; David Zawitz, Chief Operating Officer; and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verrica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verrica's SEC filings for important risk factors. Verrica cautions you not to place undue reliance on forward-looking statements and undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events or changes in expectations. In addition, during today's